All In MedTech

FDA Clearance Tracker · P000058-S088

Infuse Bone Graft

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 25, 2023

Approved

Time to decision

87 days

Received May 30, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000058-S088
Device name
Infuse Bone Graft
Applicant location
Memphis, TN
Received
May 30, 2023
Decided
Aug 25, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P000058

Device type

Device class
Class III

Every decision under product code NEK

FDA's approval statement

As written in FDA's record.

Approval for expansion of the approved indications for use of INFUSE® Bone Graft to include implantation with additional interbody fusion devices, a subset of the Anteralign Spinal System with Titan NanoLOCK Surface Technology, specifically the specified sizes of the Anteralign LS and TL systems, utilizing select open surgical procedures in conjunction with supplemental spinal fixation hardware or alone.

Source documents

Other decisions for Medtronic Sofamor Danek USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.